Global Blood Therapeutics, Inc.

Salix Pharmaceuticals, Inc.

Bionevia Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Vitae Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Chdi Foundation, Inc.

Canna Chemistries LLC

Bionevia, LLC

Travis Lee Houston

Stephan D Parent

Jeffrey S Stults

G Patrick Stahly

Dimitris Kalofonos

Isabel Kalofonos

William Martin-Doyle

Zhe Li

Petinka I Vlahova

Melanie Janelle Bevill

Nathan Carl Schultheiss

David A Claremon

Suresh B Singh

Linghang Zhuang

Lawrence Wayne Dillard

Jing Yuan

Bing Shi

Yajun Zheng

Salvacion Cacatian

Lanqi Jia

Yi Fan

Shankar Venkatraman

Stephen D Lotesta

Chengguo Dong

Andrew Marcus

Angel Morales-Ramos

Courtney S Johnson

Fang Wang

Karen Sue Gushurst

Donglai Yang

Yiduo Wu

Celia Dominguez

Leticia M Toledo-Sherman

Jian-Xie Chen

Nate Schultheiss

Hideomi Kijima

Melanie J Roe

Takayuki Fujito

Naoko Imura

Shuhei Otani

Vinod Khetarpal

Charles H Montgomery

Geetha Banda

Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.

Solid forms of a modulator of hemoglobin

Compound I as defined, having high S1Preceptor-selective agonist activity on the S1Preceptor, and the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof are provided as drug substances of pharmaceuticals.

Salt and crystal form of compound having agonistic activity to S1P5 receptor

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Crystalline salts of psilocin

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Inhibitors of the menin-MLL interaction

The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N&#x2014;((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.

Choline salt forms of an HIV capsid inhibitor

Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N&#x2014;((S-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.

Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.

Solid forms of a kynurenine-3-monooxygenase inhibitor

The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N&#x2014;((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.

Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.

Choline cocrystal of epalrestat

Growing community of inventors

Lafayette, IN, United States of America

Travis Lee Houston